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Abstract Primary melanocytic neoplasms of the central
nervous system (CNS) are uncommon neoplasms derived
from melanocytes that normally can be found in the
leptomeninges. They cover a spectrum of malignancy
grades ranging from low-grade melanocytomas to lesions
of intermediate malignancy and overtly malignant mela-
nomas. Characteristic genetic alterations in this group of
neoplasms have not yet been identiﬁed. Using direct
sequencing, we investigated 19 primary melanocytic
lesions of the CNS (12 melanocytomas, 3 intermediate-
grade melanocytomas, and 4 melanomas) for hotspot
oncogenic mutations commonly found in melanocytic
tumors of the skin (BRAF, NRAS, and HRAS genes) and
uvea (GNAQ gene). Somatic mutations in the GNAQ gene
at codon 209, resulting in constitutive activation of GNAQ,
were detected in 7/19 (37%) tumors, including 6/12 mel-
anocytomas, 0/3 intermediate-grade melanocytomas, and
1/4 melanomas. These GNAQ-mutated tumors were pre-
dominantly located around the spinal cord (6/7). One
melanoma carried a BRAF point mutation that is frequently
found in cutaneous melanomas (c.1799 T[A, p.V600E),
raising the question whether this is a metastatic rather than
a primary tumor. No HRAS or NRAS mutations were
detected. We conclude that somatic mutations in the GNAQ
gene at codon 209 are a frequent event in primary melan-
ocytic neoplasms of the CNS. This ﬁnding provides new
insight in the pathogenesis of these lesions and suggests
that GNAQ-dependent mitogen-activated kinase signaling
is a promising therapeutic target in these tumors. The
prognostic and predictive value of GNAQ mutations in
primary melanocytic lesions of the CNS needs to be
determined in future studies.
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Introduction
Primary melanocytic neoplasms of the central nervous
system (CNS) are uncommon neoplasms occurring in dif-
fuse or localized form [5, 8]. Diffuse lesions such as
melanocytosis and melanomatosis generally occur in the
setting of dermatologic syndromes (neurocutaneous mela-
nosis, nevus of Ota) [1, 16, 18]. Localized lesions present
as leptomeningeal masses and consist of a spectrum rang-
ing from ‘well differentiated’ melanocytomas to lesions of
intermediate malignancy and overtly malignant melanomas
[6]. They are derived from scattered melanocytes that are
normally present in the leptomeninges, especially at the
base of the brain, in the posterior fossa and around the
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low-grade tumors that do not invade surrounding structures
[5]. They are usually characterized by a benign clinical
course, but local recurrence can occur [14, 25]. Interme-
diate grade lesions show histological features suggestive of
aggressive behavior, such as invasion of the CNS but lack
the overt cytological atypia of melanomas [6]. The bio-
logical behavior of intermediate-grade melanocytomas is
unclear [5]. Primary melanomas of the CNS occur
throughout the neuroaxis with a predilection for the spinal
cord and posterior fossa. They are cytologically similar to
melanomas arising in other sites and may metastasize to
remote organs. Diffuse spreading of a primary meningeal
melanoma through the subarachnoid space is referred to as
meningeal melanomatosis [5, 27]. Discrimination between
primary and metastatic melanocytic lesions of the CNS is
important, because patients with metastatic disease carry a
worse prognosis, with a life expectancy of less than 1 year
in most studies [7, 23]. In addition, in some cases of pri-
mary melanomas of the CNS, long-term survival and even
‘cures’ have been documented after complete surgical
excision [6, 29]. However, especially in cases where the
melanocytic tumor presents as a solitary mass in the
meninges and the patient is not known to have a melano-
cytic tumor of the skin, this differential diagnosis can be
very difﬁcult, both at the clinical and histological levels.
While the molecular genetics of cutaneous melanomas has
been investigated in numerous studies, the genetic altera-
tions underlying primary CNS melanocytic lesions have
not yet been addressed [5]. In melanocytic lesions of the
skin—benign nevi as well as melanomas—oncogenic
mutations in signaling components of the MAP kinase
pathway are frequent [11, 22]. These mutations mostly
involve exon 15 of the BRAF gene and exon 3 (codon 61)
of the proto-oncogene NRAS. Mutations in HRAS are less
frequent [13, 20]. Recently, in uveal melanomas and in
some intradermal melanocytic lesions, such as blue nevi
and nevi of Ota, somatic activating mutations of the GNAQ
gene (or ‘G alpha q gene’) at codon 209 have been reported
[17, 32]. The GNAQ gene maps on chromosome 9q21, and
encodes a heterotrimeric GTP-binding protein a-subunit
that couples G-protein coupled receptor signaling to the
MAP kinase pathway [24]. GNAQ codon 209 mutations
form an alternative route to MAP kinase activation [32]. In
the present study, we investigated the mutation status of the
GNAQ, BRAF, NRAS, and HRAS genes in a group of 19
primary melanocytic lesions of the CNS and found that
somatic mutations in the GNAQ gene at codon 209 are
relatively frequently present in these tumors. While the
exact diagnostic, prognostic, and predictive value of GNAQ
mutations in primary melanocytic lesions of the CNS is not
yet clear, it is to be expected that a better knowledge of the
genetic background of these lesions may not only facilitate
adequate diagnosis but also identiﬁcation of (novel) ther-
apeutic targets, and thereby ultimately may have predictive
value as well.
Materials and methods
Patients and histopathology
For this retrospective study, formalin-ﬁxed and parafﬁn-
embedded (FFPE) tissues of 19 primary melanocytic
lesions of the CNS were retrieved from archives of various
Departments of Pathology in The Netherlands and
Germany. Cases from the Netherlands diagnosed between
1991 and 2009 were obtained through the Dutch nation-
wide histopathology and cytopathology data network and
archive (PALGA) [9]. The study was performed in accor-
dance with the ethical standards for this type of
investigation in The Netherlands. Histology was revised by
two pathologists (HK, BK). The diagnosis of ‘melanocy-
toma’, ‘intermediate-grade melanocytoma’ or ‘melanoma’
was based on histomorphological criteria, as described by
Brat et al. [5, 6], and immunohistochemical stains (S100
positivity and at least one additional melanocytic marker
(HMB45 or MelanA) positive in combination with lack of
EMA staining). Scoring of histology included nuclear
pleomorphism (mild, moderate or severe), mitotic activity,
necrosis, melanin pigmentation, and CNS invasion.
DNA extraction
About three manually dissected sections of 10-lm FFPE
tissue with an estimated tumor cell percentage of at least
60% were used for DNA extraction. After deparafﬁnization
and rehydration, the tissues sections were incubated in
proteinase K, followed by subsequent afﬁnity-puriﬁcation
of the DNA (QIAGEN GmbH, Germany). DNA sample
concentration was assessed spectrophotometrically (260/
280 nm using a NanoDrop spectrophotometer, Peqlab
Biotechnologies, Erlangen, Germany). DNA quality of the
samples was tested using the BIOMED-2 gene control
PCR, in which gene segments of house-keeping genes are
ampliﬁed, yielding different fragment sizes (100, 200, 300,
and 400 bp), depending on the extent of fragmentation of
the DNA [31]. All extracted DNA samples allowed
ampliﬁcation of at least the 200-bp amplicon of the BIO-
MED-2 gene control PCR.
Mutation analyses
Direct sequence analysis of the GNAQ, BRAF, NRAS, and
HRAS genes was performed on 19 primary melanocytic
lesions of the CNS. Exon 5 of GNAQ, harboring codon 209
318 Acta Neuropathol (2010) 119:317–323
123which is essential for GTP hydrolysis, was sequenced [19].
Furthermore, we performed sequence analysis of exon 15
of BRAF and exon 3 of NRAS and HRAS, since these are
well known hotspot regions for oncogenic mutations in
melanocytic lesions of the skin [2, 13, 20]. Primer
sequences used are listed in Table 1. All primers, except
for GNAQ, contained a M13 forward or reverse consensus
sequence for sequencing the different exons. PCR ampli-
ﬁcation of exon 5 of GNAQ was performed in a total
volume of 25 lL, containing 50 ng DNA, PCR-buffer IV
(Integro), 37 mM MgCl2, 250 lM of each deoxynucleotide
triphosphate, 37.5 lg bovine serum albumin (Sigma),
10 pmol of each primer, and 0.05 units of thermostable
DNA polymerase (Sigma). DNA ampliﬁcation was per-
formed in a PTC 200 Thermal Cycler (MJ Research). The
PCR was started with 5 min at 92C and followed with 35
cycles of denaturation 45 s at 94C, annealing at 62C for
45 s and extension at 72C for 45 s, followed by a ﬁnal
extension at 72C for 20 min and cooling down for 5 min
at 20C. PCR ampliﬁcation of exon 15 of BRAF and exon 3
of NRAS and HRAS were performed in a total volume of
20 lL. The PCR mix contained 50 ng DNA, buffer IV
(Integro), 3 mM MgCl2, 200 lM of each deoxynucleotide
triphosphate, 30 lg bovine serum albumin (Sigma),
10 pmol of each primer, and 0.25 units of thermostable
DNA polymerase (Sigma). DNA ampliﬁcation was per-
formed in a PTC 200 Thermal Cycler (MJ Research). The
PCR was started with 5 min at 94C and followed with 30
cycles of denaturation 45 s at 94C, annealing at 60C for
45 s and extension at 72C for 45 s, with a ﬁnal extension
at 72C for 5 min. All PCR products were puriﬁed with
MinElute plates (Qiagen). One microliter of the PCR
product was used for the sequence reaction on a ABI
PRISM 3700 DNA analyzer (Applied Biosystems). Both
strands were sequenced using the M13 primers. For all
mutations detected, normal tissue was tested to exclude
germline mutations (archival FFPE skin tissue).
Results
Patient and histopathological characteristics
Our study group consisted of 12 melanocytomas, 3 inter-
mediate-grade melanocytomas and 4 primary melanomas
of the CNS. Table 2 summarizes the respective patient and
histopathological characteristics. In each patient, no pri-
mary melanoma localizations elsewhere in the body were
known to be present. Histology revealed melanocytomas as
being often heavily pigmented lesions consisting of spindle
and/or epithelioid cells arranged in fascicles, sheets and/or
compact nests (Fig. 1a, b). Nucleoli were inconspicuous.
Mitotic activity was low (0–1 per 10 HPFs). In some cases
focal necrosis was present. Nuclear pleomorphism was
mostly mild. As summarized in Table 2 the melanocyto-
mas often recurred. Three tumors were classiﬁed as
intermediate-grade melanocytomas based on increased
mitotic activity (2–5 per 10 HPF) and CNS invasion
(patients 1, 6, and 17) (Fig. 1b, c). In the melanomas,
nuclear pleomorphism was prominent, together with con-
spicuous nucleoli, higher mitotic activity ([7 per 10 HPF)
and often extensive necrosis (Fig. 1d). All lesions were
positive for S100, HMB-45 and/or MelanA, and lacked
staining for EMA, the latter to exclude melanotic
meningioma.
Mutation analyses
In this group of 19 primary melanocytic neoplasms of the
CNS, we detected 7 mutations in the GNAQ gene (37%)
(Table 3). All mutations were present in codon 209
(p.Gln209Pro and p.Gln209Leu) and were somatic muta-
tions (Fig. 2). Of these seven GNAQ mutant lesions, six
were melanocytomas (50%) and one was a melanoma (1/4,
25%). The intermediate-grade melanocytomas (n = 3)
contained no mutations in the GNAQ gene. Of the GNAQ-
mutated melanocytomas, ﬁve were located in the lepto-
meninges of the spinal cord and one attached to the
tentorium cerebelli. All but one GNAQ-mutated melano-
cytomas were strongly pigmented. The one melanoma
containing a GNAQ mutation was located in the spinal cord
(sacral) and was mildly pigmented. Mutation analysis of
the BRAF gene revealed one BRAF mutation (c.1799 T[A,
p.V600E), in a melanoma. No HRAS or NRAS mutations
were detected in any of the samples.
Discussion
Primary melanocytic tumors of the CNS consist of a
spectrum of rare neoplasms derived from scattered mela-
nocytes located in the leptomeninges. These melanocytes
Table 1 Primers used for mutation analyses
Gene Exon Forward (Fw)
Reverse (Rv)
Primer sequence 50–30
GNAQ 5 Fw TTCCCTAAGTTTGTAAGTAGTGC
Rv ATCCATTTTCTTCTCTCTGACC
BRAF 15 Fw CCTTTACTTACTACACCTCAG
Rv AAAAATAGCCTCAATTCTTAC
NRAS 3 Fw GATTCTTACAGAAAACAAGTGG
Rv TAATGCTCCTAGTACCTGTACAG
HRAS 3 Fw CTGCAGGATTCCTACCGGA
Rv ACT TGGTGTTTGTTGATGGCA
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123are derived from the neural crest during early embryonic
development and are most frequently encountered in the
recesses of the sulci at the base of the brain and around the
brain stem and upper part of the cervical spinal cord [12].
Up to now, the genetic alterations associated with these
neoplasms are unknown. There is an increasing evidence
that melanocytic neoplasms in general are a heterogeneous
group of tumors with different molecular changes in
melanocytic lesions from different body sites. Most mel-
anocytic nevi and melanomas of the skin show oncogenic
mutations in signaling components of the MAP kinase
pathway, in particular BRAF and NRAS [11, 22], although
in uveal melanoma, Spitz nevi and blue nevi, these muta-
tions are infrequent [26]. Very recently, mutations in the
GNAQ gene at codon 209 were described as an alternative
route to MAP kinase activation in a particular subgroup of
melanocytic neoplasms, namely uveal melanomas and
speciﬁc intradermal melanocytic lesions such as blue nevi
and nevi of Ota [17, 32]. We analyzed a group of 19 pri-
mary melanocytic lesions of the CNS for hotspot
oncogenic mutations as described in melanocytic tumors of
the skin (exon 15 of BRAF gene, exon 3 of NRAS, and exon
3o fHRAS) and uvea (exon 5 of GNAQ). In 7 out of these
19 CNS melanocytic tumors a somatic GNAQ mutation
was present at codon 209 (37%). This gene is located on
chromosome 9q21 and encodes GTP-binding proteins, a
family of heterotrimeric proteins that couple cell surface
receptors to intracellular signaling pathways, such as the
MAP kinase pathway. Codon 209 encodes the catalytic
domain of GNAQ. Mutations in this catalytic domain pre-
vent hydrolysis of GTP and turns GNAQ into its active,
GTP-bound state. In uveal melanomas, identical somatic
Table 2 Patient and histopathological characteristics
Patient Sex Age Diagnosis
a Location
b Cell
type
c
Nuclear
pleomorphism
d
Mitoses
e Necrosis
f CNS
invasion
Pigmentation
g Available
follow-up
1 F 50 IM Th11-12 S ?? 2 – Yes ? na
2 F 27 MC Right cerebello-pontine
angle
E ? 0– n a
h No na
3 M 41 MC C0-C3 E ? (?)0 ? na ??? na
4n a n a M M L M
b E ?? [15 – na No na
5n a n a M C L M M x ? (?)1 ? na ? R
6 F 68 IM Cerebellar tentorium E ? 5 – Focal ? na
7 M 27 MC Cerebellar tentorium Mx ? 1– N o ?? na
8 F 44 MC Pineal region S ? 1– N o ? na
9 M 55 MC C3-6 Mx ? 0– n a ?? R
10 F 59 MM S2 Mx ??? 8 ?? Yes ? na
11 na na MC C5-6 E ? 0– n a ??? R
12 M 41 MC Th6 S ? 0 ? No ??? R
13 F 45 MC L3-4 Mx ? (?)0 – n a ??? R
14 na na MC Th11 S ? 1– n a ? na
15 M 49 MM Frontal lobe left E ?? 7 ??? na No na
16 na na MC Cerebellar S ? 0– N o ?? na
17 na na IM LM E ? 2 – Yes ??? na
18 na na MC na S ? 0– n a ??? na
19 M 7 MM Temporal lobe right E ??? [10 – Yes ? Cong.
nevus
i
F female; M male; na not analyzed/data not available; R recurred
a Diagnosis: MC melanocytoma; MM melanoma; IM intermediate grade melanocytoma
b Location: LM leptomeningeal (more speciﬁc information about location could not be retrieved)
c Cell type: S spindle; E epithelioid; Mx mixed
d Scoring of nuclear pleomorphism: ? mild; ?? moderate; ??? severe
e Number of mitotic ﬁgures per 10 HPF
f Scoring of necrosis: ? focal; ?? moderate; ??? extensive
g Scoring of pigmentation: ? mild; ?? moderate; ??? severe
h na no CNS tissue present in slide for analysis
i Patient known with a giant congenital melanocytic nevus
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123mutations of GNAQ at codon 209 have been described [21,
32]. GNAQ is important in melanocyte homeostasis and
survival of melanocytes early in neural crest development
[28].
The presence of GNAQ mutations in primary melano-
cytic neoplasms of the CNS as well as in uveal melanomas
and intradermal melanocytic proliferations such as nevi of
Ota and blue nevi [17, 32] is interesting as these lesions
share some other features. First of all, these melanocytic
tumors are non-epithelium-related neoplasms. GNAQ
mutations might, thus, preferentially occur in melanocytes
already present in extra-epithelial structures such as dermis
Fig. 1 Heavily pigmented
melanocytoma adjacent to the
thoracic spinal cord (patient 12)
consisting of spindle cells
arranged in fascicles (a)
(magniﬁcation 4009).
Epithelioid cell morphology in
an intermediate-grade
melanocytoma (patient 17)
showing increased mitotic
activity (2/10 HPFs) (b)( arrow)
(magniﬁcation 2009).
Intermediate-grade
melanocytoma showing
invasion in the thoracic spinal
cord (c) (patient 1); note the
Rosenthal ﬁber (arrow) in the
surrounding neuropil
(magniﬁcation 2009). Strong
nuclear pleomorphism and high
mitotic activity (arrows)i na
melanoma in the sacral region
(d) (patient 10) (magniﬁcation
2009)
Table 3 Mutation analysis of
the GNAQ, BRAF, NRAS, and
HRAS genes
MC melanocytoma; MM
melanoma; IM intermediate
grade melanocytoma;
na mutation status could not
reliably be evaluated due to
suboptimal DNA quality, the
DNA being derived from
formalin-ﬁxed and parafﬁn-
embedded tissues
Patient Diagnosis GNAQ BRAF NRAS HRAS
1I M w t w t n a n a
2M Cw t w t w t n a
3 MC c.626 A[C (p.Gln209Pro) wt wt wt
4M Mw t w t w t w t
5M Cw t w t w t w t
6I M w t w t w t w t
7 MC c.626 A[C (p.Gln209Pro) wt wt wt
8M Cw t w t w t w t
9 MC c.626 A[C (p.Gln209Pro) wt na wt
10 MM c.626 A[T (p.Gln209Leu) wt wt na
11 MC wt wt wt wt
12 MC c.626 A[T (p.Gln209Leu) wt na na
13 MC c.626 A[T (p.Gln209Leu) wt wt na
14 MC c.626 A[T (p.Gln209Leu) wt wt wt
15 MM wt c.1799 T[A (p.V600E) na wt
16 MC wt wt wt wt
17 IM wt wt na na
18 MC wt wt wt wt
19 MM wt wt wt wt
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123and leptomeninges. Second, they often share strong mela-
nin pigmentation. Third, in this context, the nevus of Ota is
interesting because this is a ‘dermal melanocytosis’, mostly
congenital, involving the skin innervated by the ﬁrst and
the second branch of the trigeminal nerve. The nevus of
Ota is often associated with ‘ocular melanocytosis’,
involving the sclera, conjunctiva, and uveal tract. The
involvement of different anatomical structures in the nevus
of Ota might indicate that the GNAQ gene product plays a
role in migration of melanocytes early during embryonic
development. Histology of this nevus of Ota ranges from
scattered dendritic melanocytes to a morphology strongly
resembling blue nevi [4]. These nevi of Ota are not only
associated with the development of uveal melanoma but
are also associated with the presence of CNS melanocy-
toma [25]. Thus, it appears that GNAQ mutations are
preferentially present in a group of non-epithelium-related
melanocytic lesions, sharing histological features and
occurring in an anatomical distribution indicating a possi-
ble role of GNAQ in migration of melanocytes early during
embryonic development. Interestingly, tumorigenicity
studies in nude mice with injection of human GNAQ
Q209L
resulted in heavily pigmented melanocytic tumors at the
injection site [32]. Furthermore, dominant dark skin (Dsk)
mutations that are found in mutant mice with increased
dermal melanin, are mutations of the mouse GNAQ gene,
and the hyperpigmentation in these mutant mice is due to
an increase of intradermal, but not epidermal melanocytes.
It is important to note here, however, that these Dsk
mutations are different from the oncogenic human GNAQ
mutation at codon position 209 [33]. Other studies in mice
have shown that activating mutations in GNAQ or Gal-
pha11, another gene encoding G-protein subunits, result in
an aberrant accumulation of melanin-producing melano-
cytes in the dermal layer of the skin [15].
The ﬁnding that GNAQ-mutated melanocytic lesions
(uveal melanoma, blue nevi [10, 26, 34] and our series of
melanocytic lesions of the CNS) only infrequently carry
BRAF, and NRAS mutations might be helpful for differ-
ential diagnostic purposes. For instance, in our series, one
melanoma contained a GNAQ mutation, which, in the
differential diagnosis with a metastasis of a primary cuta-
neous melanoma—often harboring BRAF or NRAS
mutations—might favor a primary location in the CNS. So,
the presence of GNAQ mutations and lack of BRAF or
NRAS mutations in melanocytic neoplasms of the CNS
seems to strongly indicate a primary CNS tumor, a diag-
nosis that has obvious prognostic implications. Vice versa,
as BRAF point mutations are a frequent event in cutaneous
melanomas [30], the one melanoma in our series with a
BRAF point mutation (case 15; c.1799 T[A, p.V600E)
might be a metastasis rather than a primary tumor. The fact
that in this patient the tumor was located in the frontal lobe
(rather than in the posterior fossa or around the spinal cord)
might support this notion. However, according to the
available data, a melanocytic tumor outside the CNS was
absent in this patient. In our study, GNAQ mutations were
preferentially present in the melanocytomas, while the
intermediate melanocytomas and melanomas were only
infrequently mutated. This might suggest that the presence
of a GNAQ mutation favors a benign or low-grade course.
On the other hand, activating GNAQ mutations are also
reported in uveal melanomas, and, in addition, are shown
to have no effect on disease-free survival in these neo-
plasms [3]. In conclusion, mutations in the GNAQ gene are
a frequent event in primary melanocytic neoplasms of the
CNS. This ﬁnding provides an important new insight in the
pathogenesis of melanocytic CNS lesions, and suggests
that GNAQ-dependent mitogen-activated kinase signaling
is a promising therapeutic target in these tumors.
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Fig. 2 SequencetracingsforGNAQsurroundingcodon209.Wildtype
(CAA) (a), CAA[CTA (b), and CAA[CCA (c). *‘W’ is the
nucleotide code forA/T accordingto theKyotoEncyclopediaof Genes
and Genomes (http://www.genome.jp/kegg/catalog/codes1.html)
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